Loading...
Loading...
LGND| Name | Value |
|---|---|
| Revenues | 41.5M |
| Cost of Revenue | 11.2M |
| Gross Profit | 30.4M |
| Operating Expense | 23.0M |
| Operating I/L | 7.4M |
| Other Income/Expense | -46.3M |
| Interest Income | 2.8M |
| Pretax | -65.4M |
| Income Tax Expense | -13.5M |
| Net Income/Loss | -51.9M |
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company that focuses on developing and acquiring technologies to aid pharmaceutical companies in discovering and developing medicines globally. The company's commercial programs include a range of pharmaceutical products used to treat multiple myeloma, COVID-19, osteoporosis, pneumonia, leukemia, and other diseases. Ligand also offers captisol-enabled formulations for various treatments and sells Captisol materials. Additionally, the company partners and licenses programs for the clinical development of treatments for cancer, seizure, diabetes, cardiovascular disease, and other conditions, generating revenue through product sales and partnerships.
